Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Image

Pancreatic cancer: The RAS paradigm shift

Journal content Created on 29 Oct 2026 PLOS Medicine

Published in

PLOS Medicine, Public Library of Science

Content

by Samuel P. Soff, Eileen M. O’Reilly

Treatment approaches for pancreatic adenocarcinoma, an aggressive disease with poor prognosis, are evolving beyond cytotoxic chemotherapy. Recent advances in RAS targeting with small molecules are redefining therapeutic paradigms. Treatment approaches for pancreatic adenocarcinoma, an aggressive disease with poor prognosis, are evolving beyond cytotoxic chemotherapy. In this Perspective, Samuel Soff and Eileen O'Reilly discuss recent breakthroughs and clinical trial results of RAS-targeting small molecule inhibitors, as well as the challenges of treatment resistance.

Eileen M. O’Reilly

Advertisement

Stats

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 22
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement